Whether you’re developing an ADC, a CAR-T or a Bispecific for the BCMA target, the inaugural BCMA Targeted Therapies Summit is the meeting for you.
With 22+ hours of content, 2 interactive workshops and over 2 hours of networking with key industry leaders, this comprehensive forum will uniquely combine distinct BCMA researchers in one setting to share lessons learned, case studies and advancements in the field.
With an emphasis on targeting BCMA to develop clinically effective therapeutics for multiple myeloma, this one-of-a-kind discussion led summit will enable you to discuss novel, cutting edge next generation BCMA Therapies, learn from the patients and deepen your understanding of developing BCMA therapies form bench to bedside.
- Gain an understanding of the challenges and opportunities of combining a BCMA therapeutic, the rationale for these combination studies and how to take them into the clinic
- Learn about next generation BCMA therapies as we hear about pre-clinical pipelines, looking to the future of the BCMA target and how the next generation modalities can overcome current challenges
- Evaluate and compare the different therapeutics being used to target BCMA in multiple myeloma, understanding the landscape of this highly competitive target
- Hear from our 23 expert speakers as we bring together the leading companies pioneering the work being done in the BCMA space from the likes of Legend Biotech, Bristol Myers Squibb, Amgen and Allogene
Download the full event guide here to view the complete agenda and speaker line-up.